VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase 3 trial responding to a combination treatment. Since the OVAL trial (NCT03398655) has met pre-specified criteria, as an interim analysis found, an independent data safety monitoring committee (DSMC) is recommending that the study continue as planned. The results of the analysis showed that at least 10%…
You must be logged in to read/download the full post.
The post More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows appeared first on BioNewsFeeds.